Avalo Therapeutics (AVTX) Competitors $7.80 +0.15 (+1.89%) As of 02/12/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends AVTX vs. CRVS, TRVI, KRRO, TSHA, TNGX, ATAI, KOD, RZLT, NMRA, and ATYRShould you be buying Avalo Therapeutics stock or one of its competitors? The main competitors of Avalo Therapeutics include Corvus Pharmaceuticals (CRVS), Trevi Therapeutics (TRVI), Korro Bio (KRRO), Taysha Gene Therapies (TSHA), Tango Therapeutics (TNGX), Atai Life Sciences (ATAI), Kodiak Sciences (KOD), Rezolute (RZLT), Neumora Therapeutics (NMRA), and Atyr PHARMA (ATYR). These companies are all part of the "pharmaceutical products" industry. Avalo Therapeutics vs. Corvus Pharmaceuticals Trevi Therapeutics Korro Bio Taysha Gene Therapies Tango Therapeutics Atai Life Sciences Kodiak Sciences Rezolute Neumora Therapeutics Atyr PHARMA Corvus Pharmaceuticals (NASDAQ:CRVS) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations, community ranking and media sentiment. Which has preferable valuation and earnings, CRVS or AVTX? Corvus Pharmaceuticals has higher earnings, but lower revenue than Avalo Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorvus PharmaceuticalsN/AN/A-$27.03M-$0.93-5.42Avalo Therapeutics$1.92M41.56-$31.54MN/AN/A Do analysts prefer CRVS or AVTX? Corvus Pharmaceuticals presently has a consensus target price of $12.38, indicating a potential upside of 145.54%. Avalo Therapeutics has a consensus target price of $40.00, indicating a potential upside of 420.83%. Given Avalo Therapeutics' higher possible upside, analysts clearly believe Avalo Therapeutics is more favorable than Corvus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Avalo Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the media refer more to CRVS or AVTX? In the previous week, Corvus Pharmaceuticals had 1 more articles in the media than Avalo Therapeutics. MarketBeat recorded 1 mentions for Corvus Pharmaceuticals and 0 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 1.87 beat Corvus Pharmaceuticals' score of -1.00 indicating that Avalo Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Corvus Pharmaceuticals Negative Avalo Therapeutics Very Positive Is CRVS or AVTX more profitable? Corvus Pharmaceuticals' return on equity of -70.71% beat Avalo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Corvus PharmaceuticalsN/A -70.71% -45.90% Avalo Therapeutics N/A -442.16%122.99% Do institutionals and insiders believe in CRVS or AVTX? 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are owned by institutional investors. 31.3% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 0.3% of Avalo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community favor CRVS or AVTX? Corvus Pharmaceuticals received 285 more outperform votes than Avalo Therapeutics when rated by MarketBeat users. Likewise, 61.91% of users gave Corvus Pharmaceuticals an outperform vote while only 33.33% of users gave Avalo Therapeutics an outperform vote. CompanyUnderperformOutperformCorvus PharmaceuticalsOutperform Votes29161.91% Underperform Votes17938.09% Avalo TherapeuticsOutperform Votes633.33% Underperform Votes1266.67% Which has more risk and volatility, CRVS or AVTX? Corvus Pharmaceuticals has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. SummaryCorvus Pharmaceuticals beats Avalo Therapeutics on 10 of the 15 factors compared between the two stocks. Get Avalo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTX vs. The Competition Export to ExcelMetricAvalo TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$85.13M$6.99B$5.76B$9.15BDividend YieldN/A2.91%5.32%4.00%P/E RatioN/A4.2459.0214.67Price / Sales41.56312.25989.2374.81Price / CashN/A75.4646.0938.87Price / Book0.845.535.125.00Net Income-$31.54M$123.50M$113.24M$222.75M7 Day Performance-6.23%-3.29%-1.43%-1.01%1 Month Performance11.79%-0.08%4.80%4.04%1 Year Performance59.67%5.40%25.30%21.71% Avalo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTXAvalo Therapeutics3.7098 of 5 stars$7.68+0.3%$40.00+420.8%+58.7%$85.13M$1.92M0.0040Positive NewsCRVSCorvus Pharmaceuticals1.967 of 5 stars$5.07-5.4%$12.38+144.1%+122.0%$325.80MN/A-5.4530Short Interest ↑TRVITrevi Therapeutics2.7828 of 5 stars$4.22+7.1%$9.31+120.7%+128.8%$324.39MN/A-9.5920KRROKorro Bio1.1557 of 5 stars$33.50-1.8%$144.00+329.9%-45.9%$313.90MN/A0.0070Gap DownTSHATaysha Gene Therapies2.6738 of 5 stars$1.53+2.0%$6.63+333.0%-5.3%$313.56M$9.92M2.43180TNGXTango Therapeutics3.6841 of 5 stars$2.91-2.3%$13.14+351.6%-80.1%$312.59M$36.53M-2.4790Short Interest ↓Analyst RevisionATAIAtai Life Sciences2.6762 of 5 stars$1.85+19.4%$9.00+386.5%+35.6%$310.43M$310,000.00-2.2880News CoverageHigh Trading VolumeKODKodiak Sciences4.2927 of 5 stars$5.82-9.1%$8.00+37.5%-7.8%$306.25MN/A-1.5990Short Interest ↑Positive NewsGap DownRZLTRezolute3.3883 of 5 stars$5.24-0.2%$24.13+360.4%+326.3%$303.62MN/A-4.1340Earnings ReportAnalyst ForecastShort Interest ↑News CoverageNMRANeumora Therapeutics4.0374 of 5 stars$1.86-3.6%$16.50+787.1%-90.6%$300.50MN/A-0.99108News CoverageATYRAtyr PHARMA2.1958 of 5 stars$3.57-7.5%$19.25+439.2%N/A$299.67M$350,000.00-3.8053Short Interest ↑ Related Companies and Tools Related Companies Corvus Pharmaceuticals Competitors Trevi Therapeutics Competitors Korro Bio Competitors Taysha Gene Therapies Competitors Tango Therapeutics Competitors Atai Life Sciences Competitors Kodiak Sciences Competitors Rezolute Competitors Neumora Therapeutics Competitors Atyr PHARMA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AVTX) was last updated on 2/13/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredHe called the top and bottom of Bitcoin nearly to the day … Here’s what he says is next.With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.